Glycogen storage disease type II
Biotech and Pharma Job Cuts: Opthea and Pfizer Restructure Amid Industry Challenges
Opthea layoffs 2025 , Pfizer staff reduction , Biotech job cuts , Pharma restructuring , Clinical trial failures , Wet AMD treatment , Cost savings programs , Pfizer San Diego layoffs , Biotech industry challenges
Eyeing precision medicines for ocular diseases, Character clinches $93M
Glycogen storage disease type II, Personality Character
EyePoint Pharmaceuticals Reports Positive Phase 2 Results for DURAVYU in Wet AMD, Challenging Established Anti-VEGF Therapies
DURAVYU, vorolanib, wet AMD, anti-VEGF therapy, EyePoint Pharmaceuticals, clinical trial results, stock price movement
Outlook Therapeutics Announces Strategic Workforce Reduction to Streamline Operations
Outlook Therapeutics, workforce reduction, biopharmaceutical company, strategic restructuring, cost-saving measures, LYTENAVA, bevacizumab gamma, wet AMD treatment.
Outlook Therapeutics to Resubmit BLA for ONS-5010 Despite Missing Primary Endpoint in NORSE EIGHT Trial
Outlook Therapeutics, ONS-5010, Lytenava, Wet Age-Related Macular Degeneration (wet AMD), Biologics License Application (BLA), NORSE EIGHT Trial, FDA Approval
Outlook Therapeutics Stock Crashes Following Clinical Trial Failure for Wet AMD Therapy
Outlook Therapeutics, OTLK, stock price, clinical trial failure, wet AMD therapy, ONS-5010, FDA filing
FDA Authorizes LumiThera’s Valeda Light Delivery System for Dry AMD Treatment
FDA authorization, Valeda Light Delivery System, dry AMD treatment, photobiomodulation, LumiThera
4DMT’s Wet AMD Gene Therapy Results Disappoint Investors, Stock Plummets
4DMT, Wet AMD, Gene Therapy, Stock Performance, Clinical Trials
Shionogi Acquires Maze’s Pompe Disease Drug Following FTC’s Sanofi Deal Halt
Shionogi, Maze, Pompe disease, drug acquisition, FTC, Sanofi, $150 million
4DMT’s Gene Therapy Reduces Eylea Injections, Advancing Plans for Phase 3 Trial in Wet AMD
Glycogen storage disease type II, 4DMT, gene therapy, Trial Phase